Blog

<h3>Hidden Side Effects of GLP-1 Medications: Fatigue, Bone Loss, and Abdominal Pain</h3><p>As GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to dominate headlines as groundbreaking treatments for obesity and type 2 diabetes, emerging real-world data has revealed several lesser-known adverse effects. These include profound fatigue, notable bone loss, and persistent abdominal pain—side effects that may not have been fully appreciated in clinical trials.</p><p>In a powerful keynote during the 2025 American Association of Clinical Endocrinology (AACE) Annual Meeting, Dr. W. Timothy Garvey, one of the field’s most respected authorities, emphasized the need for responsible prescribing and thorough patient monitoring. As the Charles E. Butterworth, Jr. Endowed Professor and Director of the University of Alabama at Birmingham (UAB) Diabetes Research Center, Dr. Garvey highlighted the potential dangers of unsupervised use and online prescriptions of GLP-1-based medications.</p><blockquote><p>You cannot practice complications-focused obesity medicine without assessing patients for those complications,” Garvey stated. “Online prescribing entirely bypasses that necessary clinical evaluation.</p></blockquote><figure id="figure-tlg1ihkbg7mb2uijv5"><img id="tlg1ihkbg7mb2uijv5" src="https://cdn.durable.co/blocks/26bSfxLG0w44tMUGw2YKda70w6n62q5uWiOOmvg4QvxX54UXYVTRr56KH3n6OUR2.jpg" alt="" title="" class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 3/2; object-position: 50% 35%;" data-corners="default" data-aspect="3:2" data-caption="" data-positionx="50%" data-positiony="35%" data-fullwidth="false" data-mce-src="https://cdn.durable.co/blocks/26bSfxLG0w44tMUGw2YKda70w6n62q5uWiOOmvg4QvxX54UXYVTRr56KH3n6OUR2.jpg" data-mce-style="aspect-ratio: 3/2; object-position: 50% 35%;"></figure><h3>Why Proper Medical Supervision Is Crucial for GLP-1 Use</h3><p>One of the key messages from Dr. Garvey’s presentation was that not all patients respond the same way to GLP-1 medications. Some individuals are hyper-responsive to low doses, experiencing rapid and sometimes excessive weight loss even at submaximal dosages. Without medical oversight, these patients risk losing more weight than is healthy, with possible cascading effects on physical and cognitive health.</p><p>“Weight loss isn’t just about seeing the number on the scale go down. It must be clinically managed,” said Garvey. “The rise in online prescribing—where patients receive medication without a full work-up—is a substandard way to treat a complex, chronic disease.”</p><figure id="figure-v22ym6y11kmb2ujym6"><img id="v22ym6y11kmb2ujym6" src="https://cdn.durable.co/blocks/28QZzI1svjvMvnzS90FnuJw6hXYfHVHw8c2aEeIU9RtVe7ZZmjxMXiks9X2O7Evf.jpg" alt="" title="" class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionx="undefined" data-positiony="undefined" data-fullwidth="false" data-mce-src="https://cdn.durable.co/blocks/28QZzI1svjvMvnzS90FnuJw6hXYfHVHw8c2aEeIU9RtVe7ZZmjxMXiks9X2O7Evf.jpg" data-mce-style="aspect-ratio: 16/9; object-position: center center;"></figure><h3>The Rise of “Fatigue Syndrome” in GLP-1 Users</h3><p>One concerning clinical pattern Garvey has observed involves a fatigue syndrome that appears in roughly 1 in 10 patients undergoing rapid or unchecked weight loss on GLP-1 medications. This syndrome is marked by:</p><ul><li>Profound tiredness</li><li>Loss of motivation and energy</li><li>Cognitive clouding (“brain fog”)</li><li>Diminished physical function at home or work</li></ul><p>Interestingly, this is not just physical fatigue but a full-body slowdown—both mental and muscular. The affected patients often have such a reduced appetite that they cannot increase their caloric intake, even when guided by a healthcare provider.</p><blockquote><p>They’re so pleased with their weight loss that they don’t recognize the toll it’s taking,” Garvey explained.</p></blockquote><p>To reverse this, clinicians may need to lower the GLP-1 dosage or even discontinue it altogether, despite patient resistance.</p><h3>Malnutrition and Dehydration: The Hidden Risks of Appetite Suppression</h3><p>This fatigue syndrome is closely tied to poor dietary intake and insufficient hydration. Patients are frequently consuming fewer than 800 calories per day—levels typically only recommended in supervised medical weight loss programs. Compounding the problem is a marked reduction in water intake due to suppressed thirst mechanisms.</p><p>This results in:</p><ul><li>Protein deficiency</li><li>Low iron and calcium levels</li><li>Chronic dehydration</li><li>Electrolyte imbalances</li></ul><blockquote><p>These patients simply aren’t eating or drinking enough to meet their physiological needs,” Garvey noted.</p></blockquote><p>Dr. Jaime Almandoz, who co-authored a review on nutritional management during anti-obesity treatment, echoed these concerns. He stressed that the average American diet is already nutritionally poor, and GLP-1-induced appetite suppression may exacerbate this deficiency unless clinicians actively guide nutritional planning.</p><blockquote><p>Without professional support, patients are unlikely to meet basic macronutrient and micronutrient needs,” Almandoz warned.</p></blockquote><p>He also pointed to fluid intake as a growing issue. “Many are dehydrated but don’t realize it—satiety affects both food and liquid consumption.”</p><h3>Lack of Functional Assessment in Obesity Clinics</h3><p>Despite the growing popularity of GLP-1 medications, there is a lack of standard guidelines for monitoring functional outcomes such as muscle strength, activity levels, or frailty risk. Almandoz called this an “unmet need” in modern obesity treatment.</p><blockquote><p>We must assess if patients are thriving, not just shrinking,” he emphasized.</p></blockquote><h3>Muscle vs. Bone: Which Loss Is More Concerning?</h3><p>It’s well known that weight loss—regardless of method—typically involves the loss of both fat mass and lean mass. With GLP-1 medications, roughly two-thirds of the lost weight is fat, while the remaining third is lean body mass (which includes muscle and bone). While clinicians often worry about muscle loss, Dr. Garvey suggested that the real concern may be hidden in the bones.</p><p>“Some loss of muscle mass is physiologically expected,” he explained. “You don’t need as much muscle to carry a lighter body. But the bone issue may be more insidious.”</p><p>A 2024 JAMA review questioned whether loss of lean body mass with GLP-1s is clinically significant, especially if physical function remains intact. Supporting this, a study of HIV-positive patients using semaglutide showed improved quality of life and no decline in physical capacity, despite muscle mass reduction.</p><p>However, bone density may tell a different story.</p><h3>Alarming Data on Bone Mineral Density (BMD)</h3><p>Garvey referenced a 2011 study involving postmenopausal women who lost weight through exercise. The troubling finding: bone density decreased during weight loss and failed to rebound even after weight regain—especially in critical areas like the spine and hips.</p><p>A more recent trial involving 195 individuals with obesity (but not diabetes) compared liraglutide alone versus liraglutide plus exercise. Only the combination group preserved bone mineral density. Those using liraglutide alone lost significant bone mass at sites associated with fracture risk.</p><p>“This raises the question: are GLP-1 users—especially older women—at higher long-term fracture risk?” Garvey asked.</p><p>A safety analysis from the SELECT cardiovascular outcomes trial showed no overall difference in fracture rates between semaglutide and placebo. However, subgroup analyses found higher rates of hip and pelvic fractures among women and those over age 75 using semaglutide.</p><p>Dr. Almandoz emphasized that as more older adults begin using GLP-1s for cardiovascular benefits, the risk of bone complications could become more pronounced.</p><p>“Everyone focuses on muscle loss, but we should be paying closer attention to bones,” he said.</p><figure id="figure-zc69rodypumb2uu31x"><img id="zc69rodypumb2uu31x" src="https://cdn.durable.co/blocks/21oduaNlvBeDAiFLZ4QWnwt80FD4lJa8hsY4BhdfXKDGjcXswsRnEifOtDv9tlqS.png" alt="" title="" class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionX="undefined" data-positionY="undefined" data-fullWidth="false"/></figure><h3>Ongoing Pharmaceutical Innovation to Mitigate Muscle and Bone Loss</h3><p>Pharmaceutical companies are now developing therapies to preserve muscle mass during weight loss. Promising agents include:</p><p>Azelaprag (a muscle growth stimulator)<br>Bimagrumab and Apitegromab (myostatin inhibitors)<br>Taldefgrobep and KER-065<br>REGN-1033 + REGN-2477 (monoclonal antibody combinations)</p><p>In parallel, amylin-based medications in development may also help preserve bone density while supporting fat loss.</p><h3>Is Abdominal Pain More Common Than Nausea?</h3><p>Perhaps the most surprising new finding relates to gastrointestinal side effects. Traditionally, GLP-1s are associated with nausea, vomiting, and diarrhea. However, recent real-world data challenge that narrative.</p><p>A cross-sectional analysis from the NIH’s “All of Us” cohort, involving over 10,000 GLP-1 users, showed:</p><ul><li>Abdominal Pain: 60%</li><li>Constipation: 30%</li><li>Diarrhea: 30%</li><li>Nausea/Vomiting: Only fourth-most reported</li></ul><p>“This really surprised me,” said Garvey. “Abdominal pain was the top symptom. We didn’t see this in the trials to the same extent.”</p><p>In contrast, the STEP 1 randomized controlled trial of semaglutide 2.4 mg reported:</p><ul><li>Nausea: 44.2%</li><li>Diarrhea: 31.5%</li><li>Vomiting: 24.8%</li><li>Constipation: 23.4%</li><li>Abdominal Pain: Only 10%</li></ul><p>This discrepancy underscores the importance of gathering and acting on post-marketing surveillance data. It also calls attention to the limitations of clinical trial environments, which may not fully capture long-term or subtle adverse effects experienced in the real world.</p><h3>Final Thoughts: A Need for Active Management and Evidence-Based Care</h3><p>GLP-1 receptor agonists are powerful tools in the treatment of obesity and metabolic disease, offering life-changing results for many patients. But as their popularity grows, so do the responsibilities of clinicians and the risks of misuse.</p><h3>Key takeaways include:</h3><p>Fatigue, bone loss, and abdominal pain are real-world side effects needing more attention.<br>Medical supervision is non-negotiable for responsible GLP-1 prescribing.<br>Nutritional and functional monitoring must become standard parts of obesity care.<br>Older adults and postmenopausal women may require extra caution due to bone-related risks.<br>Abdominal pain could be more prevalent than we thought and deserves screening.</p><p>As the landscape of obesity treatment evolves, so too must our protocols, risk assessments, and patient education efforts. We owe it to our patients not only to help them lose weight—but to ensure they thrive in the process.</p><p>#GLP-1 #weightloss #semaglutide #sideeffects &nbsp;#tirzepatide #fatigue #abdominalpain #boneloss #obesitydrugs #Ozempic #risks #Wegovy #fatigue</p>

Hidden Risks of GLP-1 Weight Loss Medications: What Patients and Doctors Need to Know

Nutritionist doctor writes the medical prescription for a correct diet on a desk with fruits, drugs and supplements, web banner and copy space template

<h2>Introduction</h2><p>In the ever-evolving landscape of weight loss trends, a new contender has emerged from the depths of social media: "Rice-Zempic." This peculiar concoction, gaining traction on TikTok, has sparked both curiosity and controversy. As health-conscious individuals seek affordable alternatives to prescription weight loss medications, it's crucial to examine this trend critically and understand its potential implications.</p><p>In this comprehensive exploration, we'll dive deep into the "Rice-Zempic" phenomenon, dissecting its origins, alleged benefits, and what medical experts really think about its efficacy and safety. By the end of this article, you'll have a clear understanding of whether this trend holds any merit or if it's just another flash in the pan of internet health fads.</p><h2>What is "Rice-Zempic"?</h2><p>Before we delve into the analysis, let's clarify what exactly "Rice-Zempic" is and how it came to be.</p><h3>Origin and Name</h3><p>The term "Rice-Zempic" is a clever portmanteau combining "rice" with "Ozempic," a popular prescription medication used for managing type 2 diabetes and promoting weight loss. This name alone suggests that the drink is positioning itself as a DIY alternative to pharmaceutical interventions.</p><h3>Rice-Zempic Recipe and Preparation</h3><p>While variations exist, the basic "Rice-Zempic" recipe typically consists of:<br>- 1/2 cup of unwashed rice<br>- 1 cup of warm or hot water<br>- Juice from half a lime</p><p>The preparation is simple:<br>1. Combine the unwashed rice with warm or hot water.<br>2. Allow the mixture to steep (some proponents suggest doing this overnight).<br>3. Strain out the rice, keeping only the starchy water.<br>4. Add lime juice to taste.<br>5. Consume the drink, usually 30-60 minutes before eating a meal.</p><figure id="figure-t7l2i7mck9m0ccl8xh"><img id="t7l2i7mck9m0ccl8xh" src="https://media.gettyimages.com/id/494494922/photo/close-up-of-a-spatula-over-a-pan-of-rice.jpg?b=1&s=2048x2048&w=0&k=20&c=c3DkXxPNXOJwquyjkidg7sSbHAfvA0IWSN2VYc2zZRc=" alt="Close-up of a spatula over a pan of rice" title="Close-up of a spatula over a pan of rice" class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionX="undefined" data-positionY="undefined" data-fullWidth="false"/></figure><h3>The Rise of "Rice-Zempic" on Social Media</h3><p>As of the time of writing, the #ricezempic hashtag on TikTok boasts over 150 posts, with users sharing their experiences and claiming dramatic weight loss results. Some of the bold assertions circulating on the platform include:</p><p>- Losing up to 14 pounds in a single week<br>- Experiencing reduced hunger throughout the day<br>- Diminished cravings for sweet foods<br>- Increased frequency of bowel movements</p><p>These eye-catching claims have undoubtedly contributed to the trend's viral nature, prompting many to wonder if they've stumbled upon a weight loss miracle hiding in their pantry.</p><h3>The Science Behind "Rice-Zempic": What Experts Say</h3><p>To separate fact from fiction, it's essential to examine the scientific basis (or lack thereof) behind "Rice-Zempic" and its purported effects. Let's break down the expert opinions on various aspects of this trend.</p><h3>Caloric Content and Meal Replacement</h3><p>Dr. Mir Ali, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center, points out one potential benefit: "It's relatively low calorie—it's just starchy water. It can be helpful for weight loss if you're using it to replace a meal."</p><p>This observation suggests that if someone were to drink "Rice-Zempic" instead of consuming a higher-calorie meal or snack, it could potentially lead to a calorie deficit, which is fundamental to weight loss.</p><h3>Satiety and Appetite Suppression</h3><p>Both Dr. Ali and Dr. Kunal Shah, an assistant professor in the division of endocrinology at the Rutgers Robert Wood Johnson Medical Center, acknowledge that the drink might induce a feeling of fullness. Dr. Shah explains, "The starch expands in your stomach and can make you feel full—but it's very short-lived."</p><p>This temporary feeling of satiety could potentially lead to reduced food intake if consumed before meals. However, it's important to note that this effect is mechanical (due to stomach expansion) rather than hormonal or metabolic.</p><p>Comparison to Ozempic and Other Medications<br>Despite its name, experts unanimously agree that "Rice-Zempic" bears no resemblance to the action of Ozempic or similar medications in terms of its effects on the body.</p><p>Dr. Ali emphasizes, "It doesn't in any way mimic Ozempic. It has no hormonal effects like Ozempic to stimulate receptors." This is a crucial distinction, as medications like Ozempic work by mimicking a hormone called GLP-1, which regulates appetite and insulin secretion.</p><h3>Nutritional Benefits</h3><p>Scott Keatley, RD, co-owner of Keatley Medical Nutrition Therapy, notes that while rice water may provide some nutritional benefits, primarily as a source of energy from its starch content, there's no evidence to suggest it has any significant impact on weight loss, especially not in the manner of anti-diabetic medications.</p><h3>Lack of Scientific Evidence</h3><p>Perhaps the most important point stressed by all experts consulted is the complete absence of scientific research supporting the efficacy of "Rice-Zempic" for weight loss. Keatley states unequivocally that the drink has "zero scientific backing."</p><figure id="figure-u51tptndlem0cchlqc"><img id="u51tptndlem0cchlqc" src="https://media.gettyimages.com/id/1169712167/photo/health-care-technology-concept-vital-sign-sensing.jpg?b=1&amp;s=2048x2048&amp;w=0&amp;k=20&amp;c=KzxICzslrlDA30-9_pseGTMKvQj-djJUERsgKlfElCI=" alt="Health care technology concept. Vital sign sensing." title="Health care technology concept. Vital sign sensing." class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionx="undefined" data-positiony="undefined" data-fullwidth="false" data-mce-src="https://media.gettyimages.com/id/1169712167/photo/health-care-technology-concept-vital-sign-sensing.jpg?b=1&amp;s=2048x2048&amp;w=0&amp;k=20&amp;c=KzxICzslrlDA30-9_pseGTMKvQj-djJUERsgKlfElCI=" data-mce-style="aspect-ratio: 16/9; object-position: center center;"></figure><h3>Potential Risks and Considerations</h3><p>While "Rice-Zempic" may seem harmless at first glance, there are several factors to consider before jumping on this trend:</p><h3>Arsenic Exposure</h3><p>Unwashed rice can contain trace amounts of arsenic, a toxic element that can be harmful if consumed in large quantities over time. By steeping unwashed rice in water, there's a potential for arsenic to leach into the drink.</p><h3>Bacterial Contamination</h3><p>According to the National Institutes of Health, up to 50% of uncooked rice samples in the U.S. may contain spores of Bacillus cereus, a bacterium that can cause food poisoning. Improper preparation or storage of "Rice-Zempic" could potentially lead to bacterial growth and subsequent illness.</p><h3>Acid Reflux Exacerbation</h3><p>Dr. Shah points out that the lime juice in the mixture may exacerbate symptoms in individuals prone to acid reflux.</p><h3>Nutritional Imbalance</h3><p>Relying on "Rice-Zempic" as a meal replacement could lead to nutritional deficiencies over time, as it lacks the balanced mix of nutrients found in whole foods.</p><h3>False Sense of Security</h3><p>Perhaps the most significant risk is psychological. Believing in a quick-fix solution like "Rice-Zempic" may prevent individuals from adopting more effective, sustainable approaches to weight management.</p><h2>The Importance of Sustainable Weight Loss Approaches</h2><p>While the allure of rapid weight loss is understandable, experts unanimously agree that "Rice-Zempic" is not a sustainable or healthy approach to weight management. Dr. Ali warns, "This weight loss will be temporary because you're not making permanent, healthy, long-term changes. Once you stop this kind of thing, the weight will come back."</p><p>Instead of seeking out quick fixes or unproven trends, health professionals recommend focusing on evidence-based strategies for long-term weight management:</p><p>1. Balanced Nutrition<br>Dr. Ali suggests reducing carbohydrate intake while increasing protein and vegetable consumption. This approach forms the basis of many successful dietary patterns.</p><p>2. Regular Physical Activity<br>Combining a nutritious diet with regular exercise is crucial for sustainable weight loss and overall health.</p><p>3. Behavioral Changes<br>Adopting healthy habits, such as mindful eating, stress management, and adequate sleep, can support long-term weight management efforts.</p><p>4. Professional Guidance<br>For individuals struggling with obesity or significant weight issues, consulting with healthcare professionals can provide personalized, medically sound approaches to weight loss.</p><p>5. Medications (When Appropriate)<br>For some individuals, prescription medications like Ozempic may be appropriate under medical supervision. However, these should never be replaced by unproven home remedies.</p><figure id="figure-ykqzfb56g8m0ccji5z"><img id="ykqzfb56g8m0ccji5z" src="https://media.gettyimages.com/id/1499666574/photo/young-business-woman-watching-live-streaming-people-using-social-media-application-concept.jpg?b=1&amp;s=2048x2048&amp;w=0&amp;k=20&amp;c=ZBBozdGIIW-rkv62-iseUc4k4-tXu6TA-fjtQu2jE8w=" alt="Young business woman watching live streaming. People using social media application concept." title="Young business woman watching live streaming. People using social media application concept." class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionx="undefined" data-positiony="undefined" data-fullwidth="false" data-mce-src="https://media.gettyimages.com/id/1499666574/photo/young-business-woman-watching-live-streaming-people-using-social-media-application-concept.jpg?b=1&amp;s=2048x2048&amp;w=0&amp;k=20&amp;c=ZBBozdGIIW-rkv62-iseUc4k4-tXu6TA-fjtQu2jE8w=" data-mce-style="aspect-ratio: 16/9; object-position: center center;"></figure><h3>The Role of Social Media in Health Trends</h3><p>The "Rice-Zempic" phenomenon highlights the powerful influence of social media platforms like TikTok in shaping health trends. While these platforms can be valuable for sharing information and experiences, they also present challenges:</p><p>1. Rapid Spread of Misinformation<br>Viral trends can quickly outpace fact-checking efforts, leading to the widespread dissemination of unverified claims.</p><p>2. Oversimplification of Complex Issues<br>Health and weight management are multifaceted topics, often reduced to simplistic "hacks" or quick fixes on social media.</p><p>3. Lack of Individual Contextualization<br>What works for one TikTok user may not be appropriate or effective for another, yet trends often present a one-size-fits-all solution.</p><p>4. Potential for Harmful Practices<br>Some trends, while seemingly harmless, may pose health risks when adopted without proper knowledge or precautions.</p><h3>Conclusion: The Verdict on "Rice-Zempic"</h3><p>After thoroughly examining the "Rice-Zempic" trend from various angles, it's clear that this social media phenomenon falls short of its lofty claims. While the drink may provide temporary feelings of fullness and could potentially aid in calorie reduction if used as a meal replacement, it bears no resemblance to the mechanisms of action of medications like Ozempic.</p><p>The lack of scientific evidence, potential risks, and unsustainable nature of this approach make it an inadvisable method for weight loss. Instead of seeking out quick fixes or unproven trends, individuals looking to manage their weight should focus on evidence-based strategies that promote long-term health and well-being.</p><p>As we navigate the ever-changing landscape of health trends, it's crucial to approach new ideas with a critical eye, seek out reputable sources of information, and consult with healthcare professionals before making significant changes to our diets or lifestyles.</p><p>Ultimately, the path to sustainable weight management and improved health lies not in a glass of rice water, but in the consistent application of proven principles: balanced nutrition, regular physical activity, and positive lifestyle changes. While these approaches may not promise overnight results, they offer something far more valuable: a foundation for lasting health and well-being.​​​​​​​​​​​​​​​​</p>

Rice-Zempic: Latest Weight Loss Trend on TikTok

<figure id="figure-os7o04f4t7m03o52ay"><img id="os7o04f4t7m03o52ay" src="https://cdn.durable.co/blocks/12MwtURw4wVogGROeVkmqsEZQGRKPCpIkKP92O5MTHz1FkaISe9A22rNhn0jeDAu.jpg" alt="Sports and workout equipment on a wooden floor with healthy snacks, weight loss and physical activity concept" title="Sports and workout equipment on a wooden floor with healthy snacks, weight loss and physical activity concept" class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionx="undefined" data-positiony="undefined" data-fullwidth="false" data-mce-src="https://cdn.durable.co/blocks/12MwtURw4wVogGROeVkmqsEZQGRKPCpIkKP92O5MTHz1FkaISe9A22rNhn0jeDAu.jpg" data-mce-style="aspect-ratio: 16/9; object-position: center center;"></figure><h2>How Tirzepatide Could Revolutionize Type 2 Diabetes Prevention</h2><p>The fight against type 2 diabetes, a condition that affects millions of people worldwide, has taken a significant step forward with recent findings about a drug called tirzepatide. Developed by Eli Lilly and Company, tirzepatide has shown remarkable effectiveness in reducing the risk of developing type 2 diabetes, especially among individuals who are overweight or obese and already at a high risk of the disease.</p><h2>The Growing Burden of Type 2 Diabetes</h2><p>Type 2 diabetes is a chronic condition that occurs when the body either resists the effects of insulin—a hormone that regulates blood sugar—or doesn’t produce enough insulin to maintain normal glucose levels. As a result, blood sugar levels rise, leading to a host of health problems, including heart disease, kidney damage, and nerve damage. The condition is often linked to obesity and physical inactivity, which have been rising dramatically worldwide.</p><p>Traditionally, managing type 2 diabetes involves lifestyle changes, such as diet and exercise, and medications that help control blood sugar levels. However, preventing the disease in the first place is a more desirable outcome, and that’s where tirzepatide comes into play.</p><h2>What is Tirzepatide?</h2><p>Tirzepatide is an innovative medication that works by mimicking the effects of two hormones involved in blood sugar control: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By activating receptors for these hormones, tirzepatide helps regulate insulin levels after meals and reduces appetite, leading to significant weight loss—a key factor in reducing the risk of developing type 2 diabetes.</p><h3>The SURMOUNT-1 Clinical Trial</h3><p>Eli Lilly conducted a significant clinical trial called SURMOUNT-1 to test the efficacy of tirzepatide in preventing type 2 diabetes among people with obesity or overweight who were at high risk of the disease. The study enrolled over 2,000 participants and divided them into groups receiving different doses of tirzepatide or a placebo. The participants were monitored for more than a year to assess how well the drug worked in reducing their diabetes risk.</p><p>The results were groundbreaking. Tirzepatide reduced the risk of developing type 2 diabetes by up to 94% among those who were at the highest risk. Even more impressive, the drug led to substantial weight loss, with some participants losing up to 20% of their body weight. Given that excess weight is a major risk factor for type 2 diabetes, this weight loss likely played a crucial role in the drug’s effectiveness.</p><h3>The Impact of Weight Loss</h3><p>Weight loss has long been recognized as one of the most effective ways to prevent or delay the onset of type 2 diabetes. When people lose weight, especially through the reduction of visceral fat (the fat that surrounds internal organs), their bodies become more sensitive to insulin, and blood sugar levels are better regulated. Tirzepatide’s dual action of lowering blood sugar and promoting weight loss makes it a particularly powerful tool in diabetes prevention.</p><h3>A Potential Game-Changer</h3><p>The potential impact of tirzepatide on public health cannot be overstated. If the drug continues to perform well in ongoing and future studies, it could become a cornerstone of diabetes prevention, especially for those who struggle with weight management and are at high risk of the disease. This could lead to a significant reduction in the incidence of type 2 diabetes, which is currently one of the most common and costly chronic conditions worldwide.</p><p>In addition to its preventive potential, tirzepatide could also be used as a treatment for those who have already been diagnosed with type 2 diabetes. The drug’s ability to improve blood sugar control and promote weight loss could help many individuals manage their condition more effectively, potentially reducing the need for additional medications or even helping some people achieve remission.</p><h3>Looking Ahead</h3><p>While the results of the SURMOUNT-1 trial are promising, more research is needed to fully understand the long-term effects of tirzepatide and its role in diabetes prevention. Eli Lilly is continuing to study the drug in various populations and settings to ensure it is safe and effective for widespread use.</p><p>If tirzepatide lives up to its potential, it could change the way we approach type 2 diabetes prevention and treatment. For now, the medical community is cautiously optimistic, awaiting further data and the eventual approval of the drug for broader use.</p><h3>Conclusion</h3><p>Tirzepatide represents a significant advancement in the fight against type 2 diabetes. By reducing the risk of developing the disease by up to 94% in high-risk individuals, this drug could become a vital tool in preventing one of the most common and challenging chronic conditions of our time. As research continues, tirzepatide holds the promise of transforming diabetes prevention and improving the lives of millions of people around the world.</p><p>For more detailed information, you can read the official news release from Eli Lilly<a data-mce-href="https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-risk-developing-type-2-diabetes-94-adults" href="https://investor.lilly.com/news-releases/news-release-details/tirzepatide-reduced-risk-developing-type-2-diabetes-94-adults" data-mce-selected="inline-boundary" target="_blank" rel="noopener"> here</a>.</p>

Tirzepatide Prevents Diabetes 84%

doctor talking to her male senior patient at office

<p>In recent years, the medical community has witnessed a significant shift in the usage patterns of GLP-1 receptor agonists, a class of medications initially developed for managing type 2 diabetes. A groundbreaking study published in the Annals of Internal Medicine has shed light on this evolving trend, revealing that an increasing number of individuals without diabetes are now turning to these drugs, primarily for weight management purposes.</p><p>The study, conducted by Dr. Yee Hui Yeo and colleagues from Cedars-Sinai Medical Center in Los Angeles, analyzed nationwide prescription data from 2011 to 2023. Their findings paint a picture of rapid change in how these medications are being prescribed and utilized across the United States.</p><p>One of the most striking observations is the dramatic increase in new GLP-1 agonist prescriptions. In 2019, the annual incidence of new prescriptions was around 0.5%. By 2023, this figure had skyrocketed to over 3%, representing a sixfold increase in just four years. This surge in popularity can be attributed to several factors, including the expanding indications for these drugs and growing awareness of their potential benefits beyond diabetes management.</p><p>Perhaps the most notable trend uncovered by the study is the changing demographic of GLP-1 agonist users. In 2019, nearly 90% of new users had type 2 diabetes. By 2023, this proportion had decreased to just over 70%. Conversely, the percentage of users without type 2 diabetes but with a BMI of 30 or greater (or a BMI of 27-30 with an obesity-related comorbidity) doubled from about 10% to roughly 25% during the same period.</p><p>This shift reflects the growing recognition of GLP-1 agonists as effective tools for weight management. The approval of semaglutide (marketed as Wegovy) for chronic weight management in 2021 marked a turning point, opening the door for broader use of these medications beyond diabetes treatment. Semaglutide, in particular, has seen a meteoric rise in popularity, accounting for 88.1% of all new GLP-1 receptor agonist prescriptions in 2023, up from 31.4% in 2019.</p><figure id="figure-rxr1ocqp8mlyy5mq71"><img id="rxr1ocqp8mlyy5mq71" src="https://media.gettyimages.com/id/1605492347/photo/a-pretty-overweight-woman-on-a-nutritionist-consultation-talking-about-a-diet-plan.jpg?b=1&s=2048x2048&w=0&k=20&c=3wLR98E0KTIUbbq2em3vgeCebbdG6Pq-f0EsUH2GbOc=" alt="A pretty overweight woman on a nutritionist consultation, talking about a diet plan." title="A pretty overweight woman on a nutritionist consultation, talking about a diet plan." class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionX="undefined" data-positionY="undefined" data-fullWidth="false"/></figure><p>Dr. Ali Rezaie, a co-author of the study, emphasized the rapid adoption of these medications, stating, "Essentially, after the medication was approved for obesity, GLP-1 RA use took off so quickly that we lost control and vision of how fast people were picking up these medications, and the trends of use are uncertain." This rapid uptake underscores the urgent need for healthcare systems to adapt to this changing landscape and ensure appropriate monitoring and management of patients using these drugs.</p><p>The study also highlighted a small but notable increase in off-label use of GLP-1 receptor agonists. The proportion of people prescribed these medications without an FDA-approved indication rose from 0.21% in 2019 to 0.37% in 2023. While this increase is relatively modest, it raises questions about the potential for misuse or overuse of these powerful medications.</p><p>It's important to note that the landscape of GLP-1 agonists continues to evolve rapidly. The recent approval of tirzepatide (marketed as Mounjaro and Zepbound) for both type 2 diabetes and chronic weight management is likely to further expand the use of GLP-1-containing agents. Additionally, the FDA's approval of GLP-1 receptor agonists for reducing cardiovascular disease risk will broaden their indications and potentially affect access.</p><p>The changing demographics of GLP-1 agonist users have significant implications for healthcare systems and policy makers. Dr. Yeo emphasized this point, stating, "These data suggest that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift. However, it also raises concerns about potential medication shortages and the need to ensure that patients with diabetes still have access to these treatments."</p><p>Indeed, the rapid increase in demand for these medications has already led to supply shortages in some areas, highlighting the need for careful planning and resource allocation. Moreover, as the use of GLP-1 agonists expands beyond diabetes management, healthcare providers must be prepared to monitor and manage a broader range of patients, each with unique needs and potential risks.</p><p>The study's findings also underscore the need for ongoing research into the long-term effects of GLP-1 agonists, particularly in non-diabetic populations. While these medications have shown promising results for weight management and cardiovascular risk reduction, their long-term safety and efficacy in diverse patient groups remain areas of active investigation.</p><p>It's worth noting that this study, while comprehensive, has some limitations. The data is derived from the TriNetX network, which, while extensive, may not be fully representative of the entire U.S. population. Additionally, the study did not capture prescriptions made outside of traditional healthcare organizations, such as through online platforms, which have become increasingly popular for weight loss medications.</p><p>In conclusion, the changing landscape of GLP-1 agonist use represents both an opportunity and a challenge for the medical community. These medications offer significant potential benefits for managing obesity and related health conditions, but their rapid adoption necessitates careful monitoring and thoughtful policy-making. As we move forward, it will be crucial to balance the expanding indications for these drugs with the need to ensure equitable access and appropriate use. The medical community must remain vigilant, continuing to study the long-term impacts of these medications while adapting healthcare systems to meet the evolving needs of patients in this new era of metabolic health management.​​​​​​​​​​​​​​​​</p>

The Changing Landscape of GLP-1 Agonist Use: Beyond Diabetes Management

Health care system and professionals. Biology lab test health care and technology.

<p>In recent years, a class of drugs commonly used to treat diabetes has shown promise in reducing the risk of several cancers associated with obesity. This exciting development comes from a large-scale study that analyzed the health records of over 1.6 million people with type 2 diabetes. The research, published in JAMA Network Open, suggests that these medications, known as GLP-1 receptor agonists, might offer additional benefits beyond blood sugar control.</p><h3>What are GLP-1 receptor agonists?</h3><p>GLP-1 receptor agonists are a type of medication used to manage type 2 diabetes. They work by mimicking a hormone in our body called glucagon-like peptide-1 (GLP-1). This hormone helps regulate blood sugar levels, slows down digestion, and can reduce appetite. Some popular drugs in this class include semaglutide (brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound).</p><h3>The Study: A Closer Look</h3><p>Researchers from Case Western Reserve University in Cleveland, led by Dr. Nathan Berger, conducted a thorough analysis of electronic health records spanning up to 15 years. They compared the cancer rates among people with type 2 diabetes who were taking different medications: GLP-1 receptor agonists, insulin, and metformin (another common diabetes drug).</p><p>The findings were striking. Compared to those using insulin, people taking GLP-1 receptor agonists had a lower risk of developing 10 out of 13 obesity-related cancers studied. These included:</p><p>1. Gallbladder cancer: 65% lower risk<br>2. Meningioma (a type of brain tumor): 63% lower risk<br>3. Pancreatic cancer: 59% lower risk<br>4. Liver cancer: 53% lower risk<br>5. Ovarian cancer: 48% lower risk<br>6. Colorectal cancer: 46% lower risk<br>7. Multiple myeloma (a blood cancer): 41% lower risk<br>8. Esophageal cancer: 40% lower risk<br>9. Endometrial cancer: 26% lower risk<br>10. Kidney cancer: 24% lower risk</p><p>It's important to note that when compared to metformin, GLP-1 receptor agonists didn't show a significant decrease in cancer risk for most types. However, there was a trend towards lower risk for colorectal and gallbladder cancers, though not statistically significant.</p><h3>What Does This Mean for Patients?</h3><p>These results are encouraging for people with type 2 diabetes, especially those who are overweight or obese. The study suggests that GLP-1 receptor agonists might offer protection against certain cancers in addition to their primary role in managing blood sugar levels.</p><p>Lindsey Wang, a medical student and co-author of the study, emphasized the importance of this research: "Given that obesity is a known risk factor for at least 13 cancer types, and considering the widespread use of GLP-1 receptor agonists for both type 2 diabetes management and weight loss, we saw an opportunity to investigate a potential link."</p><figure id="figure-u2xg0veo58ly9ap0hg"><img id="u2xg0veo58ly9ap0hg" src="https://media.gettyimages.com/id/1477214805/photo/cancer-detection.jpg?b=1&s=2048x2048&w=0&k=20&c=Z8x5PWr_3JeBodcvDtxWwGU-bbtOgAFLmhqHwaLX6Tg=" alt="Cancer Detection" title="Cancer Detection" class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionX="undefined" data-positionY="undefined" data-fullWidth="false"/></figure><h3>Cautions and Considerations</h3><p>While the results are promising, it's crucial to interpret them with caution:</p><p>1. The study was observational, meaning it can't prove that GLP-1 receptor agonists directly cause a reduction in cancer risk. Other factors could be at play.</p><p>2. When compared to metformin users, those taking GLP-1 receptor agonists showed a slightly increased risk of kidney cancer. This finding suggests the need for continued monitoring of patients using these medications.</p><p>3. The study population consisted of people who had medical encounters within a healthcare system, so the results may not apply to everyone.</p><p>4. Factors like healthcare utilization and insurance type were not controlled for in the analysis.</p><h3>The Bigger Picture: Obesity, Diabetes, and Cancer</h3><p>This study highlights the complex relationship between obesity, diabetes, and cancer. Obesity is a known risk factor for many types of cancer, and type 2 diabetes is often associated with being overweight or obese. By potentially reducing cancer risk, GLP-1 receptor agonists could offer a multi-faceted approach to improving health outcomes for people with these conditions.</p><p>Dr. Berger and his team noted that their study "adds to the growing body of evidence supporting the pleiotropic effects of GLP-1 receptor agonists on cancer prevention, including obesity-associated cancers." In other words, these medications might have wide-ranging benefits beyond their primary use in diabetes management.</p><h3>Looking Ahead: Future Research and Implications</h3><p>While this study provides valuable insights, more research is needed to fully understand the relationship between GLP-1 receptor agonists and cancer risk. Future studies might:</p><p>1. Investigate the mechanisms by which these drugs potentially reduce cancer risk<br>2. Explore whether the cancer-protective effects extend to people without diabetes who use these medications for weight loss<br>3. Conduct long-term clinical trials to confirm these observational findings</p><p>For now, patients with type 2 diabetes should continue to follow their doctor's recommendations regarding medication use. If you're concerned about your cancer risk or are interested in exploring treatment options, it's always best to discuss this with your healthcare provider.</p><p>In conclusion, this research offers hope that commonly used diabetes medications might have unexpected benefits in cancer prevention. As our understanding of these drugs grows, we may discover new ways to improve health outcomes for millions of people living with diabetes and obesity.​​​​​​​​​​​​​​​​</p>

Popular Diabetes Medication May Lower Risk of Obesity-Related Cancers

middle age asian man sleeping in his bed wearing CPAP headgear mask connected to air hose, device for people with sleep apnea

<h2>Groundbreaking Study Unveils First Drug Therapy for Sleep Apnea</h2><p>A novel drug initially developed to manage diabetes shows promising potential as a treatment for obstructive sleep apnea (OSA), significantly improving sleep quality and overall health for patients with obesity. Researchers at the University of California San Diego School of Medicine, in collaboration with international partners, spearheaded a comprehensive study that explores the effectiveness of tirzepatide, a drug known for its role in managing type 2 diabetes, in treating OSA. This sleep disorder is marked by repeated episodes of irregular breathing due to the partial or complete blockage of the upper airway.</p><p>The study's findings, published in the June 21, 2024, online edition of the New England Journal of Medicine, suggest that tirzepatide could become the first effective drug therapy for OSA, potentially improving the quality of life for millions of individuals worldwide who suffer from this condition.</p><p>“This study marks a significant milestone in the treatment of OSA, offering a promising new therapeutic option that addresses both respiratory and metabolic complications,” said Atul Malhotra, MD, lead author of the study, professor of medicine at UC San Diego School of Medicine, and director of sleep medicine at UC San Diego Health.</p><p>OSA can lead to reduced oxygen levels in the blood and is associated with a higher risk of cardiovascular issues, including hypertension and heart disease. Recent research led by Malhotra estimates that nearly 936 million people globally are affected by OSA.</p><figure id="figure-bu8fgb2zcily1j3ifl"><img id="bu8fgb2zcily1j3ifl" src="https://cdn.durable.co/shutterstock/ddwIMmGufw9l4RvIplX6FVdrBrU2xbyW2aHWgVQC1Mg959wzMj6rsAGENBj2ihYF.jpeg" alt="Snoring concept. Young woman is covering her ears. Man is snoring in bed." title="Snoring concept. Young woman is covering her ears. Man is snoring in bed." class="object-cover bg-gray-100 rounded-sm md:rounded-md lg:rounded-lg" style="aspect-ratio: 16/9; object-position: center center;" data-corners="default" data-aspect="16:9" data-caption="" data-positionX="undefined" data-positionY="undefined" data-fullWidth="false"/></figure><p>The study involved 469 participants diagnosed with clinical obesity and moderate-to-severe OSA, recruited from nine countries, including the U.S., Australia, and Germany. Participants were either using or not using continuous positive airway pressure (CPAP) therapy, the most common OSA treatment. CPAP therapy involves a machine that keeps the airway open during sleep, preventing breathing interruptions. Participants received either 10 or 15 mg of tirzepatide via injection or a placebo, and the effects of the drug were monitored over 52 weeks.</p><p>Researchers found that tirzepatide led to a significant reduction in the number of breathing interruptions during sleep, a crucial indicator of OSA severity. This improvement was substantially greater than in participants who received the placebo. Notably, some participants taking tirzepatide reached a point where CPAP therapy might no longer be necessary. This underscores the benefit of a treatment that addresses both sleep apnea and obesity rather than treating each condition separately.</p><p>Moreover, the drug therapy improved other aspects related to OSA, such as reducing cardiovascular disease risk factors and aiding in weight loss. The most common side effect reported was mild stomach issues.</p><p>“Historically, treating OSA meant using devices during sleep, like a CPAP machine, to alleviate breathing difficulties and symptoms,” Malhotra said. “However, its effectiveness relies on consistent use. This new drug treatment offers a more accessible alternative for individuals who cannot tolerate or adhere to existing therapies. We believe that the combination of CPAP therapy with weight loss will be optimal for improving cardiometabolic risk and symptoms. Tirzepatide can also target specific underlying mechanisms of sleep apnea, potentially leading to more personalized and effective treatment.”</p><p>Malhotra emphasized that introducing a drug therapy for OSA represents a significant leap forward in the field.</p><p>“It means we can offer an innovative solution, signifying hope and a new standard of care to provide relief to countless individuals and their families who have struggled with the limitations of existing treatments,” he said. “This breakthrough opens the door to a new era of OSA management for people diagnosed with obesity, potentially transforming how we approach and treat this pervasive condition on a global scale.”</p><p>Future research steps include conducting clinical trials to examine the long-term effects of tirzepatide, ensuring its efficacy and safety as a treatment for OSA. This study heralds a promising shift in how we understand and treat sleep apnea, offering a beacon of hope for millions worldwide.</p>

Dr Ozempic UK 🇬🇧

Blog

Hidden Risks of GLP-1 Weight Loss Medications: What Patie...

Rice-Zempic: Latest Weight Loss Trend on TikTok

Tirzepatide Prevents Diabetes 84%

The Changing Landscape of GLP-1 Agonist Use: Beyond Diabe...

Popular Diabetes Medication May Lower Risk of Obesity-Rel...

Mounjaro and Zepbound can Treat Sleep Apnea!